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Overview & History of HIV: 
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treatment & monitoring
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APR IL  13 ,  2020
Hello, from a distance.
Thanks SARS-CoV-2…





Virtual interaction is hard, but let’s TRY!
Your preparation will make all the difference for your learning & the group experience
◦ Spend 20 minutes prepping prior to each session
Please “interrupt” – this is not a lecture!
I’ll ask questions and you’ll answer some post-session assessments
◦ When I don’t know an answer I’ll say so, and look it up after the session
◦ (we can also poll the group for wisdom)
◦ This is NOT a test
◦ I don’t grade you J
◦ Goal: to gauge where we are and how we can be better going forward for our patients
Overall Outline
1. HIV & ART overview
◦ History, Epidemiology, transmission/risk, 
staging
◦ Med Class Overview, ART initiation
2. Treatment monitoring & Failure
◦ 2nd & 3rd line ART, toxicity/complications, 
monitoring
◦ Prevention
3. Opportunistic Infections & Hepatitis B
◦ OIs, ART considerations, Prophylaxis
◦ HBV dx, tx, surveillance, & HIV-HBV co-infection
4. Special Populations:
◦ Pregnancy, antenatal & intrapartum, infant care 
& pediatric
5. HIV/HBV Case-Based Application
1. Case Application
2. Wrap-up/review, miscellaneous items
5 session, 2 hours each
Source Materials
Liberia Integrated Guidelines for Prevention, Testing, Care, and Treatment of HIV and AIDS
◦ 5th edition, August 2019
WHO HIV Diagnosis, Treatment, and Opportunistic Infection Guidelines
◦ 2016, 2018 ART update
◦ https://www.who.int/publications/guidelines/hiv_aids/en/
WHO Hepatitis B treatment guidelines (2015)
◦ https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/
Reference Materials
Department of Health & Human Services. HIV Guidelines. USA. https://aidsinfo.nih.gov/guidelines
Fundamentals of HIV Medicine. American Academy of HIV Medicine. Oxford University Press. 2017 
Edition. 
National HIV Curriculum. University of Washington & CDC. USA. https://www.hiv.uw.edu/
HIV History
1981
AIDS identified as a clinical syndrome of immunodeficiency
1983 - 1984
HIV-1 identified as the causative agent of AIDS
Gottlieb et al 1981; Barre-Sinoussi et al 1983; Gallo et al 1984   







Sharp & Hahn 2011
Origin & Spread of HIV-1
Colonialism & forced labor
◦ Belgium & German control of Cameroon & Congo
◦ Ivory & Rubber industry
◦ Transportation Networks
◦ Trails, waterways, railways






◦ Groups M = 90-95% of HIV-1
◦ Further subtypes & clades
◦ Of little clinical relevance
◦ Most recent common ancestor = 1920
HIV-2 
◦ 30-40% homology with HIV-1 == a DIFFERENT virus
◦ 2-5% of global HIV infections
◦ Co-infection with HIV-1 is high (up to 20% rate in parts of West Africa)
◦ HIV-2 mono-infection is likely declining
◦ Found in parts of West Africa
◦ Guinea-Bissau, Gambia, Senegal, Cote d’Ivoire, Mali, Nigeria, Senegal, Sierra Leone
◦ Immigration distributes it more widely
◦ Most recent common ancestor = 1940




◦ Prevalence: 39,000 (1.4%)
◦ 32% do not know they are HIV +
◦ 35% on ART
◦ 13% with suppressed viral load
◦ Key Populations
◦ 20% prevalence in men who have sex with men (MSM)
◦ 10% prevalence in sex workers
◦ 4% prevalence in people who inject drugs (PWID)
◦ Reproductive age women have 60% higher prevalence than men
◦ Since 2010: 
◦ 31% decrease in incidence
◦ 34% decrease in AIDS-related deaths
UNAIDS 2020
Your experience
What do you estimate the HIV prevalence to be in your community, in your hospital, clinic?
◦ What are your communities high risk or key populations?
How do your patients perceive personal risk of infection?
What are harmful & helpful beliefs of HIV common in your community?
How have societal institutions (religious, educational, governmental, local leadership) responded 
to HIV in your experience?
Transmission Risk
Risk per 10,000 exposures Average exposures per infection
Blood Transfusion 9,250 ~1
Needle Sharing during Injection Drug Use 63 159
Needle Stick Injury 23 435
Receptive Anal Intercourse 138 72
Insertive Anal Intercourse 11 909
Receptive Vaginal Intercourse 8 1,250
Insertive Vaginal Intercourse 4 2,500
Oral Intercourse Low
Biting, spitting, or body fluids on intact skin Very low
Mother-to-child transmission without ART 2,500 (25%) 4







*** acute HIV, high viral load, concurrent 
STI, and mucous membrane injury all 
increase risk ***
Patel et al 2014
Testing overview
Branson et al 2014
HIV Enzyme Immunoassays (EIA)
◦ 1st gen – 1980s, high false +
◦ 2nd gen – 1980s, blood bank screening
◦ 3rd gen – 1990s, sandwiched Antibodies IgG / IgM
◦ 4th gen – 3rd gen Antibody & p24 Antigen combo
HIV Rapid Testing
◦ Determine: Ab / Ag with HIV 1/2 differentiation
◦ Bioline: IgG / IgM Ab with HIV 1/2 differentiation
◦ Uni-Gold: Ab with HIV 1/2 differentiation
HIV Nucleic Acid Amplification Test (NAAT / “viral load”)
◦ RNA, DNA
HIV Western Blot
◦ HIV lysate protein band identification in gel electrophoresis
◦ ~2 months until positive
Diagnosis by Rapid Testing
Liberia: after initial positive test > send 2 parallel confirmatory
◦ Confirmatory 1 & 2 positive = HIV +
◦ Confirmatory 1 & 2 discordant = repeat test after quality review
◦ Confirmatory 1 & 2 negative = Dried Blood Sample for NAAT
WHO: recommendation by prevalence
◦ If >5% prevalence in population tested:
◦ Diagnosis requires 2 consecutive positive tests
◦ If 1/3 assays is reactive = HIV negative
◦ If assays are reactive > non-reactive > reactive == inconclusive, repeat in 14 days
◦ If <5% prevalence in population tested:
◦ Diagnosis requires 3 consecutive positive tests
◦ If Assay 1 is reactive > Assay 2 is nonreactive == HIV negative
◦ If assays are reactive > reactive > nonreactive == inconclusive, repeat in 14 days
Testing
Liberia guideline – offer HIV testing to all patients at any facilities if:
◦ Never tested or no documentation of a test
◦ Tested negative > 3 months ago (if test indicated risk-assessment)
◦ To children under 24 mo if:
◦ Mother’s HIV status is unknown
◦ If the child is sick (even if documentation of prior negative maternal test)
◦ Index Testing:
◦ Test with partner (or via Partner Referral Slip)
◦ Test with family/children (or via Family Referral Slip)
◦ For negative tests, link to:
◦ Prevention services
◦ Retesting by risk assessment
Liberia HIV Testing Program Goals
1. Identify as many HIV+ people as possible
2. Identify patients early after infection
3. Start ART as soon as possible
Case
22 year old male
Negative HIV rapid test 1 year ago
Since that time has had 2 female sexual partners
◦ Most recent encounter was with a sex worker 2 weeks ago, unprotected vaginal intercourse
What testing scheme do you recommend, if:
1. He is asymptomatic
2. He describes fever, malaise, pharyngitis
3. He has weekly high risk sexual exposures
1. What if monthly, twice yearly…?
What would network testing mean here?
HIV & Networks
High HIV risk networks
◦ Testing in high prevalence populations is high yield for:
◦ Treatment as prevention
◦ Case identification
◦ Often socially marginalized, stigmatized
◦ Testing requires trust
◦ Social Network Strategies can identify:
◦ More cases
◦ The cases highest risk for transmission to others
◦ Leverage social influence to encourage testing
Network analysis of HIV outbreak in USA
Alpren et al 2020
Natural History of HIV
Popoola & Olufunsho 2016
WHO Staging
aStage Features Approximate CD4
1 asymptomatic Generalized lymphadenopathy >500
2 Non-AIDS defining condition <10% weight loss
Recurrent respiratory infections
Zoster, oral ulcers, dermatologic conditions
200 - 500
3 AIDS & non-AIDS >10% weight loss
Unexplained fever or diarrhea >1mo
MTB (P or EP)







Presumed Severe HIV Disease in Infants 
(PSHD)







• Severe unexplained wasting / malnutrition 
not responding to treatment 
• Pneumocystis pneumonia
• Candidiasis of oesophagus, trachea, bronchi 
or lungs
• Cryptococcal meningitis
• Toxoplasmosis of the brain (from age 1 
month)
START ART Immediately, do NOT wait for confirmatory PCR!
Basic Virology & 
Med Classes
Take out a pencil & paper!
NNRTI Non-nucleoside Reverse Transcriptase Inhibitor
NRTI Nucleoside Reverse Transcriptase Inhibitor
INSTI Integrase Strand Transfer Inhibitor
PI Protease Inhibitor
ART Regimen: Building Blocks
3 meds
◦ 2 fully active













Nucleoside Reverse Transcriptase Inhibitor
NRTI
Tenofovir [TDF]
◦ Need for HIV-HBV co-infxn [alternative = entecavir]
◦ Dose reduction for CrCl <50
Lamivudine [3TC]
◦ Well, tolerated
◦ in all 1st & 2nd line regimens
Abacavir [ABC]
◦ Hypersensitivity reaction = absolute contraindication
Zidovudine [AZT]
◦ Q12hr dosing
◦ NOT if hgb <8








Non-Nucleoside Reverse Transcriptase Inhibitor
NNRTI
Nevirapine [NVP]
◦ 1st line, but not for ART start
◦ SE: hypersensitivity reaction, rash, hepatitis
Efavirenz [EFV]
◦ 1st line, but not for ART start





Available Single Tablet Regimen
• AZT / 3TC / NVP
• TDF / 3TC / EFV – “B+”
• Very similar to “Atripla” 
Protease Inhibitor
PI
Lopinavir / ritonavir [LPV/r – Kaletra]
◦ 2nd line
◦ diarrhea
Atazanavir / ritonavir [ATV/r]
◦ 2nd line
◦ Do NOT use with rifampicin for MTB tx
◦ Benign hyperbili/jaundice
Darunavir / ritonavir [DRV + r]
◦ 3rd line





Not Available in Single Tablet Regimen
Integrase Strand Transfer Inhibitor
INSTI
Dolutegravir [DTG]
◦ 1st line for patients 30kg + without childbearing 
potential
◦ WHO: 1st line treatment for pregnant women
◦ SE mild: HA, insomnia, nausea
◦ Check LFTs before/after initiation if known liver disease




Available Single Tablet Regimen
• TDF / 3TC / DTG
ART for all
Strategy of WHO & Liberia
◦ Established personal benefit
◦ Decreased all-cause & AIDS-specific morbidity & mortality
◦ Likely population benefit
◦ treatment as prevention
ART Start – Test and Treat
PopART
4 major trials: Ya Tsie, PopART (HPTN), SEARCH, TasP
◦ 3.5 / 4 had a nonsignificant impact on population incidence
◦ Many ecological confounders, protocol changes
START 2015; Karim 2019
Preparing for ART start
Social Support





◦ Chronic Conditions – HTN, DM
Baseline labs
◦ NOT required prior to ART start
◦ WHO Stage 3/4, inpatient ART start






























32 year old female
◦ Weight loss and diarrhea for 6 months
◦ BMI now 18
◦ HIV diagnosed by rapid testing 1 month ago
How do you counsel?
What is your next step?
Monitoring Schedule
Appointments
◦ Monthly for first 6 months
◦ Space up to q 3 month appointments if virally suppressed & adherent
◦ In stable patients, 6 or even 12 months of ART may be dispensed for exceptional 
circumstances (ie, travel)
Viral Load
◦ 6 months after ARV start
◦ 12 monthly thereafter
Monitoring Treatment
Adherence
◦ Determine pill count & doses missed by last fill date
Nutritional Status
◦ Weight loss
◦ Flattening of pediatric growth curve
◦ BMI <17 in adult = malnutrition => Therapeutic Feeding
◦ MUAC <22cm in pregnancy = malnutrition => Therapeutic Feeding
◦ Weight should normalize within 6-12mo on ART
Viral Load
◦ Dried Blood Spot (DBS) = RNA PCR
CD4
◦ Baseline if available
◦ Treatment failure suspect
◦ CD4 < 200 = urine LAM & serum CrAg
◦ CD4 > 200 = no action
◦ *may be falsely elevated in acute illness
Appearance:
Weight loss / failure to thrive
Body shape change / breast swelling (men)
Swollen glands





Fever / night sweats
Vomiting / abdominal pain
Diarrhoea
Leg pain / numbness / weakness
Rash on arms, legs or trunk
Symptoms
Case (cont)
1 months later you see her in clinic
◦ Reports full adherence
◦ Diarrhea has stopped, weight is same as on start
◦ Notes that she has been feeling depressed
What do you review?
What are your next steps?
Case (cont)
She returns for 2nd month review
◦ Nightmares developed
◦ She has stopped her ART for the past 2 weeks entirely
What is your next step?
Case (cont)
You have switched your patient to a DTG-based regimen. Her 6 month viral load returns 
detectable but < 1,000.
What is your next step?
Case (cont)
She discloses that her husband is a truck driver who travels a 3-day route each week. She has 
not disclosed to him for fear of his reaction and therefore does not take ART on days when he is 
home to avoid inadvertent disclosure.
How do you respond?
Adherence
“What challenges have you had taking your ARV?”
“What days / times are you most likely to forget your ARV?”
“Everyone has difficulty taking meds every day. When was 
the last time you were not able to take your ARV, and how 
many times in the past week, month were you unable?”
Root cause: there is always a reason (or reasons)
◦ Stigma & disclosure
◦ Socio-economic barrier






• Join with daily routines (meal, cleaning)
• Cell phone alarm
• Take meds with another person
• Keep a med diary
Goal: to help the patient
• No policing
• Encourage transparency
Intensive Adherence Counseling (IAC)
for any sign of poor adherence
for any detectable Viral Load (even is <1k)
Patient & Treatment Supporter
Education on ART, adherence, monitoring, failure, & 
resistance
Indentify Specifics
• Travel, Work, Education
• Stigma, Privacy, Domestic Difficulties
• Substance Use
• Mental Health / Depression
Action Plan
• Specific
• Written on Patient Card
• Monthly appointments
• Pill Counts
• Action Plan review
• Viral Load in 3mo
Disclosure
An individual process based on trust
Pediatric Disclosure – a gradual & transparent process
Age 5-7
◦ ARV keeps their body strong to keep a germ 
“asleep”
Age 8-10
◦ Full disclosure may begin
◦ Physician may or may not assist
Age 11-13
◦ Full knowledge of HIV status
◦ Understand safe activities (hugging, kissing, 
sharing food, etc) and precautions 
(needles/razors)
Adolescence
◦ Dialogue on stigma, peer relationships, sexuality
◦ Family Planning, condoms
◦ ARV fatigue
◦ ART Teen Club
Primary Care of PLWHA
Family Planning
◦ Preventing Mother to Child Transmission (PMTCT)
◦ Assume all patients >14yo are sexually active
◦ Offer condoms to all
◦ Contraceptive Counseling
◦ Long Acting Reversible Contraceptives: DPMA (Depo-Provera), hormonal implant, Copper IUD







Cotrimoxazole Preventive Therapy (CPT)
◦ HIV exposed and infected children for age > 6 weeks
◦ Stop if confirm negative after breastfeeding
◦ HIV+ adults for life
◦ Contraindication: jaundice, renal failure, sulfa allergy
TB Preventive Treatment (TPT)
◦ All HIV+ children and adults at time of ART start
◦ Rule out active TB: no cough, weight loss (or failure to thrive in children), fever, night sweat
◦ Isoniazid (INH) x 6 months (6H)
◦ With pyridoxine
◦ Visits: start & 1, 3, & 6 months
◦ Isoniazid (INH) + Rifapentine (RFP) weekly for 3 months (3HP)
◦ Poor adherence = less effective but will not cause drug-resistant TB
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Cases (cont)
35yoM with newly diagnosed HIV ready to start treatment
◦ What are you next steps, recommendations
◦ Then your follow-up?
◦ What might be available to start in the “real world” in clinic?
6yoF newly diagnosed HIV
◦ What are your next steps?
◦ Then follow-up?
32yoF with history poor adherence who has failed efavirenz. What are your next steps?
